Arvinas logo
Close this search box.

BRD4 Degradation by PROTACs Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in DLBCL

Jing Lu Ph.D., et al.

December 1, 2015
American Society of Hematology 57th Annual Meeting and Exposition


You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content